Core Viewpoint - Apollo Biowellness, Inc. has terminated its Exclusive Distribution Agreement with Revive Regenerative, Inc. and is shifting its strategy to manage distribution and marketing internally [1][4]. Group 1: Termination of Agreement - The Exclusive Distribution Agreement between Evolutionary Biologics and Revive Regenerative has been terminated for cause, as disclosed to Revive [1]. - The termination allows Apollo Biowellness to resume management of its distribution and marketing efforts through its own initiatives and non-exclusive agreements [3]. Group 2: Strategic Direction - The company is moving in a new direction, with plans to announce further details shortly [4]. - Jim Morrison, the founder of Apollo Biowellness, is returning as CEO to lead the company in this new direction [4]. Group 3: Company Overview - Apollo Biowellness, Inc. and its subsidiary, Evolutionary Biologics, focus on the discovery, development, and marketing of products aimed at improving human health, particularly in the field of Regenerative Medicine [5]. - The company is developing natural stem cell mobilizing agents and a dual acting diet aid, targeting both consumer and professional markets [5].

Core Viewpoint - The Letter of Intent (LOI) between Apollo Biowellness, Inc. and Revive Regenerative, Inc. has expired, and the company is pursuing new partnership opportunities while addressing legal issues related to a former board member [1][3][6]. Group 1: Letter of Intent and Partnership - The LOI, which proposed a closing date of October 31, 2025, is now null and void as no extension was provided by either party [3]. - Ongoing negotiations are taking place for a newly restructured partnership between Apollo Biowellness and Revive Regenerative [3][6]. - The company is actively seeking other business opportunities in addition to the partnership with Revive Regenerative [3][6]. Group 2: Legal Issues - The company is aware of legal issues concerning Jay Lucas, a former board member who was removed in March 2025 for business reasons [4]. - Lucas Brand Equity, which had a minimal capital-raising contract with the company, is not affiliated with LB Equity Advisors Inc. [5]. - The company is investigating past relationships with Mr. Lucas to ensure compliance with legal standards [5]. Group 3: Company Overview - Apollo Biowellness, Inc. and its subsidiary, Evolutionary Biologics, Inc., focus on the discovery, development, and marketing of products aimed at improving human health [7]. - The company aims to position itself as a leader in Regenerative Medicine, utilizing biologic-based products [7]. - Current product development includes natural stem cell mobilizing agents and a dual-acting diet aid [8].

Core Insights - Apollo Biowellness, Inc. has re-engaged GSS Capital for advisory services to assist in restructuring its balance sheet and converting all convertible and secured debt to comply with the Letter of Intent with Revive Regenerative, Inc. [1] - The company aims to raise $3,500,000 in capital for growth and expansion following the merger with Revive Regenerative, Inc. [1] Group 1 - GSS Capital has a history of successfully raising significant capital for the company and will assist in the restructuring phase while working with management to secure additional capital for the merged entity [3] - Apollo Biowellness, Inc. and its subsidiary, Evolutionary Biologics, Inc., focus on the discovery, development, and marketing of products in the field of Regenerative Medicine, particularly biologic-based products [4] - The company is currently marketing patent-pending natural stem cell mobilizing agents and a dual acting all-natural diet aid [4]

Core Viewpoint - Apollo Biowellness, Inc. has received approval to file on OTCIQ and is actively pursuing multiple strategic initiatives to enhance its product offerings and market presence [1][6]. Group 1: Product Development - The company is in final negotiations with a NASDAQ-listed Israeli Bio-Tech manufacturer for the co-development of a shelf-stable biologic cosmetic named Ceilo Skin Care, set to launch in Q4 2025 [3]. - Apollo plans to introduce a unique Pet and Veterinarian Biologic product utilizing exosomes and placental products, targeting issues like arthritis and inflammation in pets, with a launch before the end of Q3 2025 [5]. Group 2: Strategic Partnerships - The company is negotiating with a large aesthetic company specializing in Laser Energy Devices for a potential merger or business combination to create a combined therapy company [4]. Group 3: Financial Strategy - Apollo is working with its debt holders and convertible note holders to restructure, refinance, or convert most positions to a preferred class of equity, aligning with management's growth financing plans for the next 12 months [6]. Group 4: Company Overview - Apollo Biowellness, Inc. and its subsidiary, Evolutionary Biologics, Inc., focus on discovering, developing, and marketing biologic-based products aimed at improving human health, positioning itself as a leader in Regenerative Medicine [7][8].